Presents findings of a study which revealed that patients who received surgery for malignant melanoma and had an elevated risk of systemic recurrence, may live a longer life, if they receive Intron A (interferon alfa-2b) recombinant. Functions of Intron A; Comparison of patients who did not ...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...
“We found people who had more non-specific mole patterns increased their melanoma risk by 2 percent with every extra mole carried,” Sturm said. “As we age, we tend to increase the amount of non-specific moles on our body, and the risk of developing melanoma increases.” A group of m...
New European approval: Relatlimab/nivolumab in first -line treatment of advanced metastatic melanoma with less than 1% tumor expression of PD-L1 来自 NCBI 喜欢 0 阅读量: 9 作者:M Boileau,L Boussemart 关键词: Immune checkpoint inhibitor Melanoma Mélanome Nivolumab Points de contrôle imm...
[4]Mao L, Lian B, Li C, et al. Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial[J]. JAMA oncology, 2023, 9(8):...
on survival outcomes in the RELATIVITY-047 study, the viability of treating kidney transplant patients with blockade inhibitors, or the possibilities surrounding combinations with a PD-L1 blockade, the gathering of new information guarantees a good sample of positive progress in the field of melanoma....
L. et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J. Clin. Invest. 115, 1903–1912 (2005). CAS PubMed PubMed Central Google Scholar Kaufman, H. L. et al. Local delivery of vaccinia virus expressing multiple ...
The panelists agreed that chemotherapy and transplantation will be mainstays of treatment for now, but they believe that the addition of targeted therapies would improve outcomes. “I think the survival curves are going up, not just because of supportive care, but because in fact we understand th...
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835–44. Article CAS Google Scholar Brufsky A, ...
et al. microRNA-10b is a prognostic biomarker for melanoma. Mod. Pathol. 29, 112–121 (2016). CAS PubMed Google Scholar Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341–347 (2010). A study that uses ...